Cambridge Healthtech Institute’s 3rd Annual

Oncolytic Virus Immunotherapy

Commercializing the Exciting Potential of Oncolytic Virotherapy

August 27-28, 2018

Oncolytic virotherapy (OV) represents an exciting new area of cancer treatment by exploiting a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following significant deals and developments by Pfizer, Celgene and Amgen, to name but a few, plus scientific developments in using OV in combination studies.

CHI’s Oncolytic Virus Immunotherapy conference brings together leading industry and academic leaders to discuss the critical steps needed to accelerate oncolytic virus immunotherapy, from delivery to combination therapy strategies, virus engineering to critical product updates.

Coverage will include, but is not limited to:

Latest updates and future directions in oncolytic virus immunotherapy

  • Update on recent deals, science and collaborations – what are the market dynamics – types of viruses (Herpes, Adeno, Vaccinia)
  • Feedback from big pharma, Pfizer, Amgen’s post T-Vec OV portfolio
  • What needs to happen to take OVs forward
  • Update from companies with late-stage products/approvals – post-market approvals

Oncolytics in an era of combination therapies

  • Are combinations the only way forward for oncolytics?
  • Examples of successful combination models – checkpoints, CAR Ts, kinase inhibitors, alternative to checkpoints, antibodies
  • Issues when combining OVs – feedback on trials
  • Evidence to support role of oncolytics as monotherapies?

Improving OV potency, targeting and efficacy

  • Engineering strategies to improve efficacy and specificity – highly armed OVs
  • New virus, mechanism of actions
  • Tumor targeted delivery – latest from Ignite
  • Impact of tumor microenvironment – vascularization

Improving delivery and administration

  • Oncolytics as a single shot vs. multiple shots – mechanisms of action, evidence-based medicine
  • IV vs. systemic - dosage, delivery, delivery when combining with PD-1s
  • Evidence to support systemic route, what data is available

Oncolytics in development: Update on major clinical and preclinical therapies

  • Clinical updates – results, safety, efficacy issues, patient selection, setting endpoints, presenting data to physicians
  • Lessons learned in the clinic – translational strategies, novel preclinical models, biomarkers
  • Regulatory expectations –what to submit to regulators, data to include, feedback

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for priority consideration is February 9, 2018.

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute

For partnering and sponsorship information, please contact:
Rod Eymael,
Manager, Business Development,
Cambridge Healthtech Institute,
Phone: (+1) 781-247-6286